Clinical Trial Update: A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of IMU-201 (PD1-Vaxx) in adults with non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IMU-201 (PD1-Vaxx) (IMU-201)

Snippet

Sponsor: Imugene Limited | Conditions: Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB | Phase 1 | Status: TERMINATED